Background: Low dietary intakes of the n-3 LCPUFAs eicosapentaenoic acid (EPA) and 2
INTRODUCTION 25
It is thought that in many countries current population intakes of the n-3 long chain 26 polyunsaturated fatty acids (n-3 LCPUFAs) eicosapentaenoic acid (EPA) and 27 decosahexaenoic acid (DHA) are lower than optimal for a variety of health outcomes (1, 2) . 28 In modern Western diets the principal source of these fatty acids is fish, particularly oily fish, 29 which are relatively unpopular foods. Coupled with this there has been a rise in recent 30 decades in intakes of oils and foods rich in n-6 LCPUFAs (2) . A decrease in the ratio of n- 3 31 LCPUFA to n-6 LCPUFA intake in the diet has, in turn, been implicated in the aetiology of 32 psychiatric disorders, including depression (3) (4) (5) (6) , which itself is a major and increasing 33 contributor to the global disease burden (7) . 34
DHA is a component of cell membrane phospholipids, and its concentration can affect 35 membrane fluidity, and activity of membrane receptors and ion channels (2, 5) . EPA is a 36 precursor of DHA and of a variety of eicosanoid immune-neuroendocrine regulatory 37 compounds, including prostaglandins, thromboxanes, prostacyclins and leukotrienes (2, 5) . 38 Animal studies have found effects of dietary concentrations of n-3 LCPUFAs on 39 phospholipid fatty acid composition and monoaminergic neurotransmission (8, 9) . 40 In relation to depression, clinical studies have revealed associations between blood 41 measures of fatty acid status and severity of depression (10) , and differences in fatty acid 42 status between people with depression and age-matched controls (11) (12) (13) , in the direction of a 43 lower n-3 LCPUFA concentration and lower n-3 LCPUFA to n-6 LCPUFA ratio in 44 depression. Another study found an inverse relationship between adipose tissue DHA 45 7 Active and placebo capsules were identical in appearance. The orange oil was included to 125 improve palatability and blinding. If bitten into, their predominant flavour was orange with 126 an oily aftertaste. These capsules were purchased from Minami Nutrition SA, Belgium who 127 prepared them especially for the trial. They were supplied to participants in sealed, child-safe, 128 plastic containers labelled with the participant's ID number. 129
130

Outcome measures 131
The primary outcome was depressed mood at 12 weeks follow-up, measured by the 132 depression subscale of the DASS (long form) (25) . Secondary outcome measures were the 133 Beck Depression Inventory (BDI) (26) , the anxiety and stress subscales of the DASS, the 134
General Health Questionnaire (GHQ) (27) , the state anger subscale of the State-Trait Anger 135
Expression Inventory (STAXI) (28) , mood assessed using a diary and an emotional probe 136 task, and cognitive function assessed using further computer-based tasks. 137
For the mood diary, participants recorded their mood on ten clusters of descriptors 138 (e.g., happy/cheerful/light-hearted, drowsy/sluggish/fatigued, clear-headed) rated on 100 mm 139 uni-polar line scales anchored at either end with 'not at all' and 'extremely'. Ratings were 140 made at six pre-specified times (8 am, 11 am, 1 pm, 3 pm 6 pm and 9 pm) daily for 3 days. A 141 similar method was previously used successfully in a study of the effects of cholesterol-142 lowering on mood (29) . The emotional probe task was based on methods described by 143
MacLeod and Mathews (30) and Mogg and Bradley (31) . It formed part of the battery of 144 computer-presented cognitive tasks detailed below. Each trial of the emotional probe task 145 began with the appearance of a central fixation cross, which was replaced by two words, one 146 appearing on the left and one on the right of the computer screen for 500 ms. Next, 147
immediately after the words disappeared, a left or right pointing arrow (the probe) appeared 148 on the left or right of the screen, and the participant had to indicate as quickly as possible8 with a key press the direction of the arrow. One of the words presented was physically or 150 socially threatening in nature (e.g., coffin, pathetic) and one was neutral, matched for initial 151 letter, word length, number of syllables and, as far as possible, frequency of general use with 152 the threatening word (e.g., collar, portable). The advantage of implicit (reaction time) 153 measures of this type is that they are free from potential biases, such as impression 154 management and social desirability, which can undermine the validity of mood 155 questionnaires and interview methods. 156
Other aspects of cognitive function, including speed of information processing, 157 reasoning using lexical and numerical cues, impulsivity and working memory were assessed 158 using the following tasks: simple reaction time (32) , lexical decision (33), digit-symbol 159 substitution (34), impulsivity (32) , and N-Back (35) . Previous studies have found differences 160 in performance between depressed and non-depressed individuals on all these tasks (31, 33, 161 36-38) , and two have found improvement in performance alongside improvement in 162 depressed mood during treatment for depression (33) (34) (35) (36) (37) . All cognitive tasks were 163 programmed and presented using E-Prime 1.0 (Psychology Software Tools Inc., Pittsburgh) 164 run on networked PCs with 15-in colour monitors and standard keyboards. They were 165 undertaken in the above order, with the emotional probe task occurring second to last, as a 166 single battery lasting 45 minutes, and were preceded on every occasion by a practice battery 167 lasting 5-10 minutes, which contained all the tasks in shortened form. The purpose of this 168 practice was to familiarise and re-familiarise participants with the tasks. 169
Compliance with the trial protocol was assessed using: self-reported number of days 170 on which capsules were taken; a count of the number of capsules returned; and plasma fatty 171 acid composition measured from fasting venous blood samples collected from all participants 172 willing to provide blood. Analysis of fatty acid composition was carried out using gas The trial was presented to participants as a study of the effects of 'dietary supplements 220 on health and well-being' and they were told that the capsules contained components of a 221 natural healthy diet (e.g., vitamins and oils). Fish and fish oils were not mentioned explicitly 222 in this context. Success of these blinding procedures was evaluated by asking participants subgroups. These pre-specified subgroup analyses were based on DASS depression score at 236 baseline (< 14 versus ≥ 14, which is the boundary between mild and moderate depression 237 severity (25) ). 238
The mood diary data were subjected to factor analysis (using the method of principal 239 factoring with varimax rotation) to ascertain if there was a smaller number of underlying 240 dimensions by which they could be characterised. Scores on the resulting latent variables 241
were then subjected to the between-group comparisons described above using linear 242 regression models (except that, due to larger amounts of missing data, baseline values were 243 not included in these analyses). 244 12 placebo groups (Table 2 and Figures 2 and 3) . Mean (± SD) ages of the two groups were 249 respectively 38.0 ± 13.5 and 38.2 ± 13.7 years, and 85 (78%) and 83 (76%) were female. The 250 mean (± SD) DASS depression score and age of the 28 participants (13 in the EPA+DHA 251 group and 15 in the placebo group) failing to complete their full course of supplements were 252 10.2 ± 5.2 and 34.6 ± 11.5 years, respectively, and 24 (86%) were female. Reasons for non-253 completion of supplementation were: not having sufficient time to devote to the trial, given 254 by 6 and 7 participants (EPA+DHA and placebo respectively); the development of health 255 problems unrelated to participation in the trial, given by 2 participants in each group; the 256 development of health problems related to taking the capsules, given by 2 participants 257 receiving placebo ('allergy' to citrus flavouring, intolerance of high fat content); one person 258 became pregnant (placebo); one person left the country (EPA+DHA), and 4 and 3 259 participants were not contactable following their previous visit. 260
Mean (± SD) DASS depression at screen 2 of the 218 participants who subsequently 261 entered the trial was 15.9 ± 4.8, and their mean (± SD) PUFAQ score was 0.34 ± 0.52. 262
Although depressed mood had improved somewhat compared to baseline (Table 2) , it 263 remained above the euthymic ranges on both the DASS (scores of 10-13 are categorised as 264 mild depression (25) ) and BDI (scores of 10-18 are categorised as mild to moderate 265 depression (Beck and Steer, 1987) ). DASS depression at baseline was correlated with BDI (r 266 = 0.62), GHQ (r = 0.66), STAXI state anger (r = 0.28), DASS anxiety (r = 0.45) and DASS 267 stress (r = 0.55) scores (n = 218, all P values < 0.01). 268
Results (mean ± SD) for compliance as measured by self-report (% of days on which 269 the capsules were consumed) and pill count at week 12 were, respectively, 98 ± 3% and 101 270 ± 11% in the EPA+DHA group, and 98 ± 3% and 102 ± 11% in the placebo group. Results 271 are above 100% because pill counts indicated that some participants exceeded the prescribed 272 dose. There were similarly high levels of compliance at week 4. From baseline to week 12, Mood and other aspects of mental health were not affected by EPA+DHA 282 supplementation (Table 2) . Specifically, the primary outcome of depressed mood improved 283 over the 12 weeks of the intervention, but to a similar extent in EPA+DHA and placebo 284 groups. All the values in the 95% confidence interval for the adjusted difference in DASS 285 depression score are smaller than those specified as clinically significant in the a priori 286 sample size calculation. 287
Analyses based on data only from participants who fully completed the trial also 288 showed no effects of the intervention, as did per protocol analyses that additionally omitted 289 two EPA+DHA participants who had high plasma EPA+DHA concentrations at baseline due 290 to fish oil supplement use (which was not recognised until debriefing at the end of the trial). 291
Per protocol results for DASS depression are shown in Table 2 . 292
Regarding the subgroup analysis, while DASS depression scores fell to a greater 293 extent in the subgroup with higher scores at baseline (Figure 3) , there was no evidence of a 294 differential effect of EPH+DHA across the two subgroups (week 12 supplementation by 295 depression group interaction, P = 0.90). 296
The factor analysis performed on the mood diary data identified three components 297
with eigen values > 1, which corresponded to 'dysphoric mood' (relaxed/calm (-), bad mood14 (+), happy/cheerful/lighthearted (-), tense/anxious/nervous/on edge/stressed (+), 299 sad/gloomy/miserable (+)), 'drowsiness', and 'alertness and clear-headedness'. Not all 300 participants successfully completed their mood diaries. Analysable data were available for 77 301 EPA+DHA and 74 placebo participants at week 12. Drowsiness, and alertness and clear-302
headedness, but not dysphoric mood, varied as a function of time of day (P < 0.001). All 303 three mood components were found to be unaffected by supplementation (P values > 0.1 for 304 effects of supplementation and supplementation by time of day interaction effects). Results 305 (mean ± SD) for dysphoric mood were as follows: EPA+DHA = 34.7 ± 13.4, placebo = 35.0 306 ± 11.9; adjusted difference between means = -0.2, 95% CI = -4.2 to 3.8, P = 0.93. 307
308
Cognitive function 309
There was no evidence of effects of supplementation on cognitive function (Table 2) . 310
Although there was a suggestion that performance on the impulsivity task might be improved 311 by EPA+DHA, the number of tests performed means that this should be regarded with 312 caution. 313
The negative emotional probe bias scores at baseline indicate a propensity to avoid 314 attending to threat words (P = 0.012 from a t-test for all 211 individuals combined). This 315 propensity was stronger in more depressed participants (mean ± SD bias scores = -11.9 ± 316 22.2 and -1.5 ± 27.3 ms for DASS depression at baseline ≥ 14 and < 14, respectively; 317 difference between means adjusted for age and gender = -10.4, 95% CI = -2.7 to -18.1, P = 318 0.009); however, supplementation did not affect this measure in either subgroup (all P levels 319 > 0.1). 320 15 received, and this not differ between groups (numbers saying 'active' and 'placebo' 324 respectively, were 38 and 58 for the EPA+DHA group, and 31 and 63 for the placebo group; 325 P = 0.34 from a chi-squared test). Twelve participants said that they had received cod liver 326 oil, fish oil, or omega-3 oils, of which 10 were in the EPA+DHA group. Other guesses at 327 what the capsules contained included vitamins (39) , minerals (7), oils (5) and herbal extracts 328 (3) . 329
The main finding of this trial is the lack of a clinically important or statistically 332 significant effect of n-3 LCPUFA supplementation on depressed mood among people with 333 moderate depression. The confidence interval for the primary outcome (DASS depression 334 score) excluded both a clinically beneficial and harmful effect. Similarly, other measures of 335 depressed mood were not improved by EPA+DHA over placebo. Indeed, all measured 336 aspects of mood and mental health, including anxiety, stress, and cognitive function, were 337 unaffected by supplementation, even in the subgroup with a higher level of depression on 338 entry into the trial. Great care was taken to conceal the specific nature of the intervention, and 339 blinding was successful. 340
To the authors' knowledge, this is the largest trial investigating the effects of n-3 341 LCPUFA supplementation on depressed mood to be completed to date. The EPA+DHA 342 supplement was well tolerated, and the loss to follow-up of 13% was lower than anticipated 343 for a non-clinical group participating in a lengthy protocol. It is unlikely that the absence of 344 beneficial effects can be explained by the level or duration of supplementation. Compliance 345 appeared to be good, and after 12 weeks plasma EPA+DHA concentration in the 346 supplemented group was twice that of the placebo group. A similar effect on blood 347 concentrations of EPA+DHA was reported recently in a trial using a higher level of At baseline in the present trial there was attentional avoidance of the threat words 362 (e.g., injury, violence, failure, criticised) presented in the emotional probe task. This 363 avoidance was more marked in the more depressed group. While attentional vigilance for 364 threat related stimuli is commonly found among those with generalized anxiety disorder, 365 results for depression are less clear, with relatively few previous reports of emotional probe 366 tasks revealing attentional biases in depression (31) . Similar to the results for the self-report 367 measures of depressed mood (DASS depression and BDI), attentional avoidance of threat 368 words declined over the 12 weeks of the trial, and again there was no effect of 369 supplementation, even for the more depressed group. In view of the interest in possible 370 effects of n-3 LCPUFAs in the treatment of 'impulsivity disorders' (3), it is noteworthy that 371 17 analyses this must be treated with considerable caution. Furthermore, even if it is confirmed, 374 the extent to which such an effect might predict a benefit for impulsive behaviour generally, 375 or in relation to ADHD, aggression or even suicide risk (5) is far from certain. 376
The evidence from this trial and previous studies therefore does not favour a benefit 377 for depressed mood or cognitive function of increased n-3 LCPUFA intake. An association 378 between dietary intake of n-3 LCPUFAs and depressed mood has been found in various 379
populations (e.g., 16, 17) ; however, analysis of cross-sectional data on nearly 3000 of the 380 people screened during recruitment for the present trial did not confirm such a relationship 381 when level of social and economic deprivation and age were taken into account (18) . 382
Furthermore, depressed mood among the participants entering the trial was not related to 383 plasma n-3 LCPUFA concentrations. Adding the present trial to a meta-analysis of the other 384
RCTs on this subject (20) confirms an overall negligible effect size for n-3 LCPUFA 385 supplementation versus placebo (Figure 3 ). This meta-analysis also reveals evidence of 386 heterogeneity and substantial funnel plot asymmetry, probably due to publication bias and/or 387 differences in trial populations (20) . 388
The participants for this trial were recruited from community-based settings and in 389 general had mild to moderate depressive symptoms. Those previous studies that have shown 390 benefits had much smaller sample sizes, and involved individuals with more severe 391 depressive symptoms from clinical settings. It remains that the present randomized trial is the 392 largest and most relevant to a primary care population. It did not provide any evidence to 393 support the use of n-3 LCPUFAs to improve depressed mood. 394 N-back, number correct 13.1 ± 5.9 11.9 ± 5.4 12.5 ± 6.5 11.6 ± 6.3 12.1 ± 6.9 11.0 ± 6.5 0.4 (-1.1 to 1.9) 0.58
1 Mean difference between treatment groups (i.e., EPA+DHA minus placebo) at week 12, adjusting for score at baseline, and age and gender. Note that for all variables lower scores signify better mood or cognitive function, except for the N-back task where higher scores are better, and the emotional probe task where zero scores indicate a lack of attentional bias.
2 For difference at week 12.
3 Data are means (± SD). 4 Numbers vary because at baseline accuracy was too low to calculate reaction times (emotional probe task), or because participants failed to complete a task, sometimes due to equipment breakdown. FIGURE 1. 
Exclusions
